Alar Pharmaceuticals (ROCO:6785) YoY EBITDA Growth : -119.31% (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Alar Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Alar Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -119.31%.

Alar Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2025 was NT$-0.06.

Alar Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Alar Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alar Pharmaceuticals YoY EBITDA Growth Chart

Alar Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

-51.49

61.91

51.87

1,445.33

-91.06

Alar Pharmaceuticals Quarterly Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															200.69	195.52	-929.41	-93.31	-119.31

Alar Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Alar Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(0.618	-	6.915)	/	\| 6.915 \|
=	-91.06 %

Alar Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(-0.056	-	0.29)	/	\| 0.29 \|
=	-119.31 %

Alar Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Alar Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Alar Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alar Pharmaceuticals Inc (ROCO:6785) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 32, Keya Road, 5th Floor, Daya District, Taichung, TWN, 407

Website

https://www.alarpharm.com

Alar Pharmaceuticals Inc is a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs.

Alar Pharmaceuticals Headlines

No Headlines